REG - LungLife AI, INC - Publication of AR and Accounts & Notice of AGM

LungLife AIAnnouncement

08/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220408:nRSH7034Ha&default-theme=true

RNS Number : 7034H  LungLife AI, INC  08 April 2022

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Publication of Annual Report and Accounts & Notice of AGM

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces that the Annual Report and Accounts, Notice of Annual
General Meeting ("AGM"), Form of Direction and associated Form of Proxy are
now available on the Company's website and have been posted to those
shareholders who have opted out of electronic communications.

 

The documents are available here: https://investors.lunglifeai.com/
(https://investors.lunglifeai.com/)

 

The Company's AGM will be held at 2:00 P.M. (BST) on 11 May 2022, at Investec
Bank plc, 30 Gresham Street, London, EC2V 7QP.

 

Following the easing of coronavirus (COVID-19) restrictions in the UK, the
Board has made arrangements to enable shareholders to attend the Annual
General Meeting in person. However, in light of the uncertainty as to any
further COVID-19 measures that may be put in place by the UK Government and
bearing in mind the inherent risk of large gatherings, the Company encourages
shareholders to consider submitting their voting instructions in advance by
appointing the Chairman of the meeting as their proxy, rather than attending
and voting on the day. This will ensure that votes are registered in
accordance with shareholders' wishes regardless of any restrictions or
disruption around the Annual General Meeting and will also help protect the
health and safety of shareholders, directors and other necessary attendees.
Depending on the public health situation, we may impose additional procedures
or limitations on attendees beyond any described in this Notice of the Annual
General Meeting. The Board will make arrangements for shareholders to listen
to proceedings remotely should they wish to do so. We will announce details of
how to listen to the meeting remotely and any other significant changes to the
meeting arrangements via RNS and on our website at
https://investors.lunglifeai.com/ (https://investors.lunglifeai.com/)

 

We strongly encourage you to vote by proxy, whether or not you plan to attend
the Company's Annual General Meeting in person. Alternatively, you may
register your votes on the resolutions of the Annual General Meeting by
completing and returning the proxy form that accompanies the Notice in
accordance with the instructions printed on the proxy form. Or by using the
link www.signalshares.com and selecting LUNGLIFE AI, INC (You will need to log
into your Signal Shares account or register if you have not previously done
so. To register you will need your Investor Code, this is detailed on your
share certificate or available from our Registrar, Link Group).

 

If your holding of Common Shares is by way of dematerialised depository
interests representing underlying Common Shares ("Depository Interests"), you
can vote through the CREST system or by returning a Form of Direction to the
Depositary. Further instructions are set out in the Notes to the Notice of
Annual General Meeting, available on the Company website.

 

The results of voting on the resolutions will be announced via a regulatory
information service and posted on the Company's website as soon as practicable
possible after the AGM.

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Daniel Adams / Virginia Bull / Cameron MacRitchie

 Walbrook PR Limited                                  Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                     (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings / Phillip Marriage    Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About Lunglife AI

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABKOBNPBKDFQK